| Not Yet Recruiting | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the NCT06794073 | Shanghai Zhongshan Hospital | N/A |
| Active Not Recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) NCT05797246 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can NCT05617755 | Arsenal Biosciences, Inc. | Phase 1 |
| Completed | Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy NCT05152927 | University of California, San Francisco | N/A |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151 | Sheba Medical Center | Phase 2 |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Recruiting | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma NCT04008082 | Eisai Co., Ltd. | — |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer NCT03562897 | Catalysis SL | Phase 2 |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities NCT03072472 | South Tyneside and Sunderland NHS Foundation Trust | N/A |
| Completed | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452 | Syndax Pharmaceuticals | Phase 1 |
| Completed | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778 | Syndax Pharmaceuticals | Phase 1 |
| Unknown | HR Versus RFA for HCC in Patients With PHT NCT02192671 | Guangxi Medical University | Phase 3 |
| Unknown | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous In NCT01995942 | Royal Marsden NHS Foundation Trust | — |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Terminated | Intended Use Study of the BD SurePath Plus™ Pap NCT01234480 | Becton, Dickinson and Company | — |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Unknown | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks NCT01037049 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Terminated | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer NCT00672009 | Cedars-Sinai Medical Center | Phase 2 |
| Unknown | Low Rectal Cancer Study (MERCURY II) NCT02005965 | Royal Marsden NHS Foundation Trust | — |
| Terminated | Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin NCT00481936 | Sesen Bio, Inc. | Phase 1 |
| Completed | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combin NCT00337428 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combi NCT00325130 | Merck Sharp & Dohme LLC | Phase 3 |
| Approved For Marketing | Vorasidenib Expanded Access Program NCT05592743 | Servier | — |